Scholarlink

<p>Immune checkpoint inhibitors (ICIs) are now a standard treatment for small cell lung cancer (SCLC). In certain cases, cross-line ICI therapy may still provide clinical benefit after disease progression; however, reports detailing the associated adverse events—particularly hematologic toxicities—remain scarce. We present a case of grade 4 immune thrombocytopenia that occurred in a patient with extensive-stage SCLC shortly after switching from durvalumab (anti-PD-L1) to camrelizumab (anti-PD-1) upon progression. The diagnosis was confirmed by strongly positive anti-platelet antibodies (4+) after excluding other causes. Combination therapy with high-dose methylprednisolone and intravenous immunoglobulin, supplemented with recombinant human thrombopoietin (rhTPO) in accordance with Chinese clinical guidelines, led to rapid platelet recovery within one week. No recurrence occurred during subsequent non-ICI chemotherapy, strongly supporting a probable association with camrelizumab. To our knowledge, this represents the first documented case of severe thrombocytopenia occurring in the context of and likely triggered by camrelizumab following durvalumab-to-camrelizumab sequence in SCLC, which highlights the potential for severe irAEs upon switching ICI classes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Grade 4 thrombocytopenia with PD-1 inhibitors following progression of PD-L1 inhibitor therapy in small cell lung cancer: a case report and literature review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月30日

查看全文
  • An Wang,
  • Yi Dong,
  • Dongxiao Wu,
  • Yibing Bai,
  • Xuhui Yang,
  • Haitao Tao

摘要

Immune checkpoint inhibitors (ICIs) are now a standard treatment for small cell lung cancer (SCLC). In certain cases, cross-line ICI therapy may still provide clinical benefit after disease progression; however, reports detailing the associated adverse events—particularly hematologic toxicities—remain scarce. We present a case of grade 4 immune thrombocytopenia that occurred in a patient with extensive-stage SCLC shortly after switching from durvalumab (anti-PD-L1) to camrelizumab (anti-PD-1) upon progression. The diagnosis was confirmed by strongly positive anti-platelet antibodies (4+) after excluding other causes. Combination therapy with high-dose methylprednisolone and intravenous immunoglobulin, supplemented with recombinant human thrombopoietin (rhTPO) in accordance with Chinese clinical guidelines, led to rapid platelet recovery within one week. No recurrence occurred during subsequent non-ICI chemotherapy, strongly supporting a probable association with camrelizumab. To our knowledge, this represents the first documented case of severe thrombocytopenia occurring in the context of and likely triggered by camrelizumab following durvalumab-to-camrelizumab sequence in SCLC, which highlights the potential for severe irAEs upon switching ICI classes.